---
title: The MedTech Value Chain: Every Player from Manufacturer to Patient
description: The MedTech value chain runs from manufacturer through importer, distributor, hospital procurement, clinician, payer, and patient. Here is how MDR maps to each.
authors: Tibor Zechmeister, Felix Lenhard
category: MedTech Startup Strategy & PMF
primary_keyword: MedTech value chain
canonical_url: https://zechmeister-solutions.com/en/blog/medtech-value-chain
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# The MedTech Value Chain: Every Player from Manufacturer to Patient

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The MedTech value chain is the full set of actors a medical device passes through on its way from a manufacturer's workbench to a patient's body. In a typical European deal that chain contains seven roles — manufacturer, authorised representative, importer, distributor, hospital procurement, clinician user, and patient — with a payer sitting alongside as the entity that funds the whole thing. The MDR assigns legal obligations to the first four under Articles 10, 13, and 14; the last three carry no MDR obligations but hold all the power over whether the device actually gets used. Founders who only understand the manufacturer seat lose control of the other six.**

**By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.**

---

## TL;DR

- The MedTech value chain in Europe has seven functional seats: manufacturer, authorised representative, importer, distributor, hospital procurement, clinician user, and patient — with a payer funding the transaction from the side.
- The MDR defines three of those seats as "economic operators" with explicit legal obligations: manufacturer under Article 10, importer under Article 13, and distributor under Article 14. Authorised representatives are covered under Article 11.
- Hospital procurement, clinicians, and patients have no MDR obligations, but they decide whether a device is ever purchased, used, or trusted. Founders who ignore them fail at market entry even if the CE mark is perfect.
- The payer — insurer, statutory fund, or national health service — is not in the MDR at all. It sits outside the regulation and above the hospital, and it decides whether the hospital gets paid for using your device.
- A device that only has a manufacturer strategy is a device that leaks margin and control at every downstream seat. A device with a full value chain strategy keeps control of its intended purpose all the way to the patient.
- Subtract to Ship applied to the value chain means: know every seat, sell to the ones that buy, comply with the ones that MDR names, and never outsource a seat you cannot afford to lose.

---

## Why the value chain matters more than founders think

Most founders build a mental model of their business that has two boxes. Box one is "we build the device." Box two is "customers buy it." Everything between those two boxes is fog.

The fog is where MedTech companies lose control of their own product.

Between the manufacturer's workbench and the patient's bedside, a medical device in Europe passes through a sequence of hands that each take a cut — of margin, of control over the story, of influence over whether the device is ever actually used. Some of those hands have legal obligations under the MDR. Some do not. All of them can stop the device from reaching a patient, and every one of them has a different reason to say yes or no.

Understanding the full chain is not an academic exercise. It changes who you hire, what you write in your contracts, how you price the device, what your intended purpose says, and what your first commercial conversations look like. A founder who only knows the manufacturer seat walks into the market like someone who has only ever seen one side of a chess board.

This post walks through every seat in the chain, names the pain each seat feels, and maps the MDR obligations to the ones the Regulation actually reaches.

## The manufacturer — MDR Article 10

The manufacturer is the entity that carries the entire regulatory weight of the device. MDR Article 10 sets out the general obligations: ensure the device conforms to the Regulation before placing it on the market, run a QMS proportionate to the risk class, prepare and maintain the technical documentation in Annex II, perform the conformity assessment procedure, draw up the EU declaration of conformity, affix the CE marking, run post-market surveillance, and meet reporting obligations. (Regulation (EU) 2017/745, Article 10.)

Every obligation that a founder associates with "MDR compliance" sits here. If the device fails a field safety check, the manufacturer is the entity a Notified Body or competent authority calls. If the post-market surveillance data reveals a trend, the manufacturer is the entity that has to act. If an incident is reportable under vigilance, the manufacturer is the entity that reports it.

Two consequences matter for founders. First, the manufacturer is a legal status, not a commercial one. You do not choose to be the manufacturer — you are the manufacturer the moment you place the device on the market under your own name. Second, you cannot outsource these obligations. You can hire consultants, contract out production, and delegate activities, but the legal accountability stays with the manufacturer. Article 10(14) requires the manufacturer to have a person responsible for regulatory compliance (PRRC) available within the organisation. (Regulation (EU) 2017/745, Article 10, paragraph 14.)

For a startup, the manufacturer seat is the one everyone expects you to sit in. The mistake is assuming it is the only seat that matters.

## The authorised representative — MDR Article 11

For any manufacturer not established in the European Union, the MDR requires an authorised representative located in the Union. The authorised representative is the bridge between a non-EU manufacturer and the EU regulatory system. Their role is defined in Article 11, and their obligations include verifying that the EU declaration of conformity and technical documentation have been drawn up, keeping a copy available, cooperating with competent authorities, and acting on behalf of the manufacturer on certain reporting duties. (Regulation (EU) 2017/745, Article 11.)

For an EU-based startup this seat is often empty in the home market, but it reappears the moment the company starts selling into a country outside the Union and needs a mirror-image representative there (under that country's rules, not the MDR). For a non-EU manufacturer trying to place a device on the EU market, this seat is mandatory and non-trivial to fill. The authorised representative carries joint liability for defective devices under Article 11(5), which is the reason good authorised representatives charge real money and vet their manufacturers carefully before signing. (Regulation (EU) 2017/745, Article 11, paragraph 5.)

A founder who is building in Austria, Germany, France, or the Netherlands and selling first into the EU will often not think about this seat for years. A founder who is building in Switzerland, the UK, the US, or anywhere else will meet this seat on day one.

## The importer — MDR Article 13

The importer is the entity that first places a device from outside the Union onto the EU market. MDR Article 13 defines the importer's obligations, and they are more substantial than most founders expect. The importer has to verify, before placing the device on the market, that it bears a CE marking, that the EU declaration of conformity has been drawn up, that the manufacturer has an authorised representative where required, that the device is labelled correctly, and that the UDI has been assigned. The importer also has to indicate their own name, registered trade name or trade mark, and registered place of business on the device or its packaging or accompanying documents. (Regulation (EU) 2017/745, Article 13.)

Article 13 also places ongoing obligations on the importer: ensuring storage and transport conditions do not jeopardise compliance, keeping a register of complaints and incidents, cooperating with the manufacturer on corrective action, and reporting suspected non-conformities to the manufacturer and — in certain cases — to competent authorities.

Why this matters for a founder inside the EU: your distributors in non-EU markets become importers under equivalent regimes, and your import partners for components or finished goods that cross into the Union from a non-EU factory create importer obligations that have to be assigned to a named entity. Importer status is not optional. The question is always which legal entity is holding it.

## The distributor — MDR Article 14

The distributor is any actor in the supply chain, other than the manufacturer or the importer, who makes a device available on the market up until the point of putting into service. MDR Article 14 sets out distributor obligations, which are lighter than the importer's but still real. Before making a device available, the distributor has to verify that the device bears the CE marking, that the EU declaration of conformity has been drawn up, that the device is accompanied by the information required under Article 10(11), that the importer has complied with Article 13(3) where applicable, and that a UDI has been assigned. (Regulation (EU) 2017/745, Article 14.)

Distributors also have to ensure that storage and transport conditions comply with the manufacturer's specifications, keep a register of complaints, cooperate with competent authorities on corrective action, and inform the manufacturer of any suspected non-conformity.

For a MedTech startup, the distributor seat is the most common commercial partner outside direct sales. A distributor in Germany who takes on your device, holds stock, ships it to hospitals, and handles local returns is carrying Article 14 obligations whether they realise it or not. A good distributor understands this. A bad distributor signs a contract and then discovers at the first audit that they have regulatory duties they have not built the processes to meet — which blows back on you, because the contract you signed is also the document the competent authority will read.

The practical consequence: distributor contracts are regulatory documents, not just commercial ones. They have to name the Article 14 obligations, define who does what, and match the reality of how the device moves. Sloppy distributor contracts are one of the fastest ways for a small company to import risk from a partner who does not have its house in order.

## Hospital procurement — no MDR obligations, all the power

From here on, the chain leaves the MDR's definition of economic operators and enters the buying side. MDR Article 2(30) defines "economic operator" as manufacturer, authorised representative, importer, distributor, or system/procedure pack assembler. (Regulation (EU) 2017/745, Article 2, paragraph 30.) Hospitals are not on that list. Hospital procurement has zero obligations under the MDR in its capacity as a buyer.

That does not mean hospital procurement is irrelevant. It means the opposite. Because the MDR does not constrain what procurement can ask for, procurement imposes its own set of requirements on top of the regulation — vendor qualification, quality agreements, supplier audits against ISO 13485, insurance, delivery terms, IT security reviews for connected devices, integration with hospital information systems, infection control sign-off, and everything else a modern hospital does to protect itself.

This is the seat where most early-stage MedTech deals die. The founder shows up with a CE certificate and assumes that means the device is ready to sell. Procurement asks for a quality agreement template, a PRRC contact, an ISO 13485 certificate scope statement, a cybersecurity declaration, and a list of incidents reported in the last 24 months. The founder has none of these ready. The file sits at the bottom of the pile.

Everything we wrote in [decision-making units in MedTech sales](/blog/decision-making-units-medtech-sales) applies here. Procurement is one of the four DMU roles. Unlike the clinical champion, procurement will not fight for your device. Their job is to reduce operational risk to the hospital, and a startup with messy paperwork is operational risk.

## The clinician — the user who decides the device's fate

The clinician — surgeon, nurse, technician, radiologist, GP — is the person who actually touches the device. They have no MDR obligations as users beyond the general duty of care that comes with their profession. But they have enormous influence over whether the device is ever used at all.

A clinician who likes the device becomes the internal champion who pushes procurement, persuades colleagues, and defends the device when it has a bad day. A clinician who hates it can kill it in a hallway conversation. The clinician experiences the device as workflow — time per case, friction, cognitive load, reliability under pressure, and whether the device fits the fifteen other things they do in a shift.

The manufacturer's obligation to the clinician lives in the instructions for use, the training material, and the usability engineering file under EN 62366-1:2015+A1:2020. The MDR does not tell you to keep the clinician happy; it tells you the device has to be safe and usable for its intended user population. Whether the clinician actually adopts the device is a commercial question the Regulation leaves entirely to you.

## The patient — the beneficiary who is never in the room

The patient is the reason the device exists, the lens through which the regulator evaluates every claim, and the seat that is almost never present when the purchase decision is made. The patient has no MDR obligations. The patient also has no vote at the procurement meeting.

The manufacturer represents the patient in the clinical evaluation under MDR Article 61 and Annex XIV — the entire point of clinical evaluation is to demonstrate that the device's benefits to the patient outweigh the risks. But on the commercial side, the patient is represented by the clinician's judgement and by the hospital's reputation concern. A device that genuinely helps patients but cannot demonstrate it in a way the clinician trusts does not get used. A device that helps patients but the hospital's reputation cannot defend — because of poor evidence or a confused intended purpose — also does not get used.

Patient benefit is the one thing a founder can never cut from the story. Every other seat in the value chain is, in the end, accountable to whether the patient actually got better.

## The payer — outside the MDR, above the hospital

Sitting alongside and above the hospital is the payer: the insurer, the statutory health fund, the national health service, or — in some models — the patient paying out of pocket. The payer is not an economic operator under the MDR. The MDR does not regulate reimbursement at all. Reimbursement lives under national health system rules that differ by country, by region, and sometimes by hospital category.

The payer's role in the value chain is to decide whether the hospital gets paid for using your device. If there is a billing code that covers the device, the hospital can treat the purchase as revenue capture. If there is no code, the hospital absorbs the cost against an already-allocated budget. The difference between those two situations is usually the difference between a device that sells and a device that does not.

The payer seat is where many founders discover, too late, that a CE mark does not equal market access. The CE mark gets the device onto the market legally. The reimbursement decision determines whether the market can actually afford it. Founders who map the value chain without the payer seat have missed the single biggest non-regulatory blocker to commercial success.

## How MDR obligations sit across the chain

If you lay the seven seats and the payer out on one line, the MDR touches the first four and leaves the rest alone.

- Manufacturer — full obligations under Article 10.
- Authorised representative — obligations under Article 11, joint liability under Article 11(5).
- Importer — obligations under Article 13, including verification, labelling, record-keeping, and cooperation.
- Distributor — obligations under Article 14, lighter but still real.
- Hospital procurement — no MDR obligations. Imposes its own requirements.
- Clinician user — no MDR obligations. Decides adoption.
- Patient — no MDR obligations. Represented by the clinical evaluation.
- Payer — no MDR obligations. Decides reimbursement under national rules.

The regulation's reach stops at the distributor. That is not a gap in the MDR. It is the MDR's deliberate scope. The Regulation governs placing on the market and making available; it does not govern how hospitals choose suppliers, how clinicians choose techniques, or how payers choose codes. Those decisions sit in a different legal and commercial universe, and founders have to handle them with different tools.

## Where founders lose sight of the chain

The consistent pattern across the MedTech failures we have watched is a founder who built a strategy for one seat — usually the manufacturer seat — and assumed the rest of the chain would sort itself out.

The importer seat gets skipped and a non-EU partner quietly starts shipping devices into the Union without an assigned importer of record, creating a compliance gap that surfaces at the first customs inspection. The distributor seat gets signed with a generic commercial contract that does not name Article 14 obligations, and the first field safety corrective action becomes a finger-pointing exercise. Procurement gets ignored until the day the founder asks "why are we not closing" and discovers the file has been stuck in vendor onboarding for four months. The payer gets ignored until launch, when the finance director of the first hospital asks which billing code covers the device and nobody has an answer.

Every one of those failures is a value chain mapping failure. The device might be perfect. The intended purpose might be airtight. The CE certificate might be clean. None of that rescues a founder who did not know the full list of seats that have to say yes.

## The Subtract to Ship angle on the value chain

Every seat in the value chain should be mapped, named, and assigned to a specific legal entity and a specific commercial owner. If a seat is unassigned, it is drag — latent risk that will surface at the worst possible moment. If a seat is overstaffed — two distributors in the same territory, three authorised representatives for the same region, a procurement strategy with no single owner — it is also drag.

The subtraction is ruthless.

- Every seat in the chain gets one owner on your side. One legal entity holding importer status per market. One distributor contract per territory with clean Article 14 language. One procurement lead per target hospital. One clinical champion per target site.
- Every MDR obligation that applies to a seat you control is mapped to a specific article and built into the contract or SOP that governs that seat. No handshake agreements with importers. No vague distributor contracts. No "we will figure out procurement later."
- Every seat you do not control — clinician, patient, payer — gets a named answer to its pain, written into your pitch and into the intended purpose statement under MDR Article 2(12). (Regulation (EU) 2017/745, Article 2, paragraph 12.)
- Every seat that does not earn its place gets cut. A distributor in a market you cannot service is drag. An authorised representative in a market you do not sell into is drag. A payer strategy for a code you cannot qualify for is drag.

Read [the Subtract to Ship framework for MDR](/blog/subtract-to-ship-framework-mdr) for how this discipline runs across the whole certification project, and [decision-making units in MedTech sales](/blog/decision-making-units-medtech-sales) for the companion view from the buying side.

## Reality Check — where do you stand on your value chain?

Answer these honestly. If more than two are weak, you do not yet understand your own value chain.

1. Can you list every legal entity that will touch your device between your workbench and the patient, and name the MDR article that applies to each one?
2. Do you know whether you need an authorised representative in any of your target markets, and have you named the entity that will hold that role?
3. For every market you plan to sell into, do you know who the importer of record will be, and have their Article 13 obligations been written into the contract?
4. Do your distributor contracts name Article 14 obligations explicitly, or are they generic commercial contracts you copied from another industry?
5. Have you spoken directly to hospital procurement at a target buyer about what vendor documentation they will require before onboarding you?
6. Do you know which clinicians will actually touch the device, and have you tested the usability against their real workflow?
7. Do you know which payer funds the transaction at your target buyer, whether a billing code exists, and whether the buyer already has that code active?
8. If a field safety corrective action had to run tomorrow, do you know exactly which entity in the chain would do what, with which paperwork, under which clause of which contract?

## Frequently Asked Questions

**What is the MedTech value chain?**
The MedTech value chain is the full set of actors a medical device passes through between the manufacturer and the patient. In a typical European deal it contains seven roles — manufacturer, authorised representative, importer, distributor, hospital procurement, clinician user, and patient — with a payer funding the transaction from the side. The MDR defines legal obligations for the first four under Articles 10, 11, 13, and 14. The others have no MDR obligations but decide whether the device is ever bought, used, or trusted.

**Which actors in the MedTech value chain have legal obligations under the MDR?**
The MDR imposes obligations on four categories of economic operator: manufacturers under Article 10, authorised representatives under Article 11, importers under Article 13, and distributors under Article 14. Hospitals, clinicians, patients, and payers have no MDR obligations. The regulation's reach stops at the point where a device is made available on the market; everything downstream of that — purchase decisions, clinical use, reimbursement — sits under different legal and commercial regimes.

**What is the difference between an importer and a distributor under the MDR?**
An importer is the entity that first places a device from outside the EU onto the Union market. Their obligations under Article 13 include verifying CE marking and the EU declaration of conformity, putting their own name on the device or its packaging, and keeping a register of complaints. A distributor is any actor downstream of the importer who makes the device available on the market. Their obligations under Article 14 are lighter but still include verification of the CE marking, storage conditions, and cooperation on corrective actions.

**Do hospitals have MDR obligations?**
Hospitals do not have MDR obligations as buyers or users of medical devices. The MDR regulates economic operators, which are defined in Article 2(30) as manufacturers, authorised representatives, importers, distributors, and system/procedure pack assemblers. Hospitals fall outside that list. They do impose their own requirements on manufacturers — vendor qualification, quality agreements, cybersecurity reviews, integration requirements — but those are commercial, not regulatory.

**Where does reimbursement fit in the value chain?**
Reimbursement sits alongside the hospital as an external layer. The payer — an insurer, a statutory health fund, or a national health service — is not regulated by the MDR at all. National rules govern reimbursement, and they differ by country and sometimes by region. The reimbursement decision determines whether the hospital can treat the purchase as revenue capture or has to absorb it as cost. Founders who map the value chain without a payer seat miss the single biggest non-regulatory blocker to market access.

**Can a founder cut out the distributor and sell direct to hospitals?**
Sometimes, and for a small number of deals it is cheaper and gives the founder more control. Direct sales also mean the founder carries every Article 14 obligation a distributor would otherwise carry, plus the logistics, the local language support, the local invoicing, and the on-site presence. For a small number of large hospitals in a home market, direct sales can work. Scaling across multiple countries almost always forces the distributor seat back into the chain.

## Related reading

- [What Is the EU Medical Device Regulation?](/blog/what-is-eu-mdr) — the hub post for MDR fundamentals.
- [MDR Article 10: Manufacturer Obligations Explained](/blog/mdr-article-10-manufacturer-obligations) — the deep dive on the manufacturer seat.
- [MDR Article 13 and 14: Importer and Distributor Duties](/blog/mdr-article-13-14-importer-distributor) — the companion post on the downstream economic operators.
- [The No-Bullshit Guide to MDR Compliance for First-Time Founders](/blog/no-bullshit-mdr-guide-first-time-founders) — the direct orientation on what MDR actually asks of a startup.
- [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) — the hub post for MedTech PMF and how the value chain shapes it.
- [Decision-Making Units in MedTech Sales](/blog/decision-making-units-medtech-sales) — the companion post on the buying side of the chain.
- [MedTech Reimbursement Strategy](/blog/medtech-reimbursement-strategy) — the payer seat, covered in depth.
- [Selling to Hospital Procurement](/blog/selling-hospital-procurement) — the operational rules for working with procurement teams.
- [Distributor Contracts for Medical Devices](/blog/distributor-contracts-medical-devices) — how to draft contracts that carry Article 14 obligations cleanly.
- [Authorised Representatives for Non-EU Manufacturers](/blog/authorised-representative-non-eu-manufacturer) — the Article 11 seat, explained for founders outside the Union.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) — the methodology behind this post.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, consolidated text. Articles cited: Article 2(30) definition of economic operator; Article 2(33) definition of manufacturer; Article 2(34) definition of authorised representative; Article 2(36) definition of importer; Article 10 general obligations of manufacturers; Article 11 authorised representative; Article 13 general obligations of importers; Article 14 general obligations of distributors. Official Journal L 117, 5.5.2017.
2. Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices. Official Journal L 80, 20.3.2023.

---

*This post is part of the MedTech Startup Strategy and PMF series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The manufacturer seat is the one everyone expects you to sit in. The other six seats are where founders lose control of their own product. Map the full chain before you ship, or pay the lesson in leaked margin and missed deals.*

---

*This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*